A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 131, Issue 3, 2012, Pages 899-906

  Somlo, G ^a   Martel, C L ^a   Lau, S K ^a   Frankel, P ^a   Ruel, C ^a   Gu, L ^a   Hurria, A ^a   Chung, C ^a   Luu, T ^a   Morgan Jr , R ^a   Leong, L ^a   Koczywas, M ^a   McNamara, M ^a   Russell, C A ^b   Kane, S E ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Breast cancer; Gefitinib; HER2; Phosphatase and tensin homolog; Protein kinase A; Trastuzumab

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN DARPP 32; PROTEIN P70; S6 KINASE; TRASTUZUMAB;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; ELECTROLYTE DISTURBANCE; FATIGUE; FEMALE; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; INFECTION; LEUKOPENIA; LUNG TOXICITY; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PAIN; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84856234624     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1850-2     Document Type: Article

References (35)

1. MA Owens BC Horten MM Da Silva 2004 HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues Clin Breast Cancer 5 1 63 69 15140287 10.3816/CBC.2004.n.011 1:CAS:528:DC%2BD2cXltFygsbc%3D
2. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 4785 177 182 3798106 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D
3. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 783 792 10.1056/NEJM200103153441101 11248153 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D
4. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman SM Swain TM Pisansky L Fehrenbacher LA Kutteh VG Vogel DW Visscher G Yothers RB Jenkins AM Brown SR Dakhil EP Mamounas WL Lingle PM Klein JN Ingle N Wolmark 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 16 1673 1684 10.1056/NEJMoa052122 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F
5. I Smith M Procter RD Gelber S Guillaume A Feyereislova M Dowsett A Goldhirsch M Untch G Mariani J Baselga M Kaufmann D Cameron R Bell J Bergh R Coleman A Wardley N Harbeck RI Lopez P Mallmann K Gelmon N Wilcken E Wist P Sanchez Rovira MJ Piccart-Gebhart 2007 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 9555 29 36 10.1016/S0140-6736(07)60028-2 17208639 10.1016/S0140-6736(07)60028-2 1:CAS:528:DC%2BD2sXit12itg%3D%3D
6. CL Vogel MA Cobleigh D Tripathy JC Gutheil LN Harris L Fehrenbacher DJ Slamon M Murphy WF Novotny M Burchmore S Shak SJ Stewart M Press 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 3 719 726 11821453 10.1200/JCO.20.3.719 1:CAS:528:DC%2BD38XhsVGmt7o%3D
7. Y Lu X Zi Y Zhao D Mascarenhas M Pollak 2001 Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J Natl Cancer Inst 93 24 1852 1857 11752009 10.1093/jnci/93.24.1852 1:CAS:528: DC%2BD38XltVWluw%3D%3D
8. CA Ritter M Perez-Torres C Rinehart M Guix T Dugger JA Engelman CL Arteaga 2007 Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network Clin Cancer Res 13 16 4909 4919 10.1158/1078-0432.CCR-07-0701 17699871 10.1158/1078-0432.CCR-07-0701 1:CAS:528:DC%2BD2sXptVGmtLg%3D
9. CT Chan MZ Metz SE Kane 2005 Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3 K) and epidermal growth factor receptor (EGFR) kinase inhibitors Breast Cancer Res Treat 91 2 187 201 10.1007/s10549-004-7715-1 15868447 10.1007/s10549-004-7715-1 1:CAS:528:DC%2BD2MXjvVWjsrs%3D
10. KD Courtney RB Corcoran JA Engelman 2010 The PI3K pathway as drug target in human cancer J Clin Oncol 28 6 1075 1083 10.1200/JCO.2009.25.3641 20085938 10.1200/JCO.2009.25.3641 1:CAS:528:DC%2BC3cXktF2lt7w%3D
11. B Dave I Migliaccio MC Gutierrez MF Wu GC Chamness H Wong A Narasanna A Chakrabarty SG Hilsenbeck J Huang M Rimawi R Schiff C Arteaga CK Osborne JC Chang 2011 Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers J Clin Oncol 29 2 166 173 10.1200/JCO.2009.27.7814 21135276 10.1200/JCO.2009.27.7814 1:CAS:528:DC%2BC3MXhvVahtbg%3D
12. R Nahta D Yu MC Hung GN Hortobagyi FJ Esteva 2006 Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer Nat Clin Pract Oncol 3 5 269 280 10.1038/ncponc0509 16683005 10.1038/ncponc0509 1:CAS:528:DC%2BD28Xltlagtbg%3D
13. TW Miller JT Forbes C Shah SK Wyatt HC Manning MG Olivares V Sanchez TC Dugger N de Matos Granja A Narasanna RS Cook JP Kennedy CW Lindsley CL Arteaga 2009 Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells Clin Cancer Res 15 23 7266 7276 10.1158/1078-0432.CCR-09-1665 19934303 10.1158/1078-0432.CCR-09-1665 1:CAS:528:DC%2BD1MXhsFSnu73P
14. L Gu SK Lau S Loera G Somlo SE Kane 2009 Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines Clin Cancer Res 15 23 7196 7206 10.1158/1078-0432.CCR-09-0585 19920112 10.1158/1078-0432. CCR-09-0585 1:CAS:528:DC%2BD1MXhsFSnu7zK
15. KL Blackwell HJ Burstein AM Storniolo H Rugo G Sledge M Koehler C Ellis M Casey S Vukelja J Bischoff J Baselga J O'Shaughnessy 2010 Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J Clin Oncol 28 7 1124 1130 10.1200/JCO.2008.21.4437 20124187 10.1200/JCO.2008.21.4437 1:CAS:528: DC%2BC3cXktF2ltLo%3D
16. M Fukuoka S Yano G Giaccone T Tamura K Nakagawa JY Douillard Y Nishiwaki J Vansteenkiste S Kudoh D Rischin R Eek T Horai K Noda I Takata E Smit S Averbuch A Macleod A Feyereislova RP Dong J Baselga 2003 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 12 2237 2246 10.1200/JCO.2003.10.038 12748244 10.1200/JCO.2003.10.038 1:CAS:528:DC%2BD2cXpsVGqu7w%3D
17. Albain K, Elledge R, Gradishar WJ, Hayes DF, Rowinsky E, Hudis C, Pusztai L, Tripathy D, Modi S, Rubi S (2002) 20: Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 76 (Suppl. 1). doi: 10.1023/A:1021560101414
18. J Baselga J Albanell A Ruiz A Lluch P Gascon V Guillem S Gonzalez S Sauleda I Marimon JM Tabernero MT Koehler F Rojo 2005 Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer J Clin Oncol 23 23 5323 5333 10.1200/JCO.2005.08.326 15939921 10.1200/JCO.2005.08. 326 1:CAS:528:DC%2BD2MXpslOrtLs%3D
19. M Marty F Cognetti D Maraninchi R Snyder L Mauriac M Tubiana-Hulin S Chan D Grimes A Anton A Lluch J Kennedy K O'Byrne P Conte M Green C Ward K Mayne JM Extra 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 19 4265 4274 10.1200/JCO.2005.04.173 15911866 10.1200/JCO.2005.04.173 1:CAS:528:DC%2BD2MXms12gs70%3D
20. RS Herbst G Giaccone JH Schiller RB Natale V Miller C Manegold G Scagliotti R Rosell I Oliff JA Reeves MK Wolf AD Krebs SD Averbuch JS Ochs J Grous A Fandi DH Johnson 2004 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 5 785 794 10.1200/JCO.2004.07.215 14990633 10.1200/JCO.2004.07. 215 1:CAS:528:DC%2BD2cXpsVKjur0%3D
21. N Robert B Leyland-Jones L Asmar R Belt D Ilegbodu D Loesch R Raju E Valentine R Sayre M Cobleigh K Albain C McCullough L Fuchs D Slamon 2006 Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer J Clin Oncol 24 18 2786 2792 10.1200/JCO.2005.04.1764 16782917 10.1200/JCO.2005.04.1764 1:CAS:528:DC%2BD28XntV2hu7g%3D
22. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 282 457 481 10.2307/2281868
23. J Sun 2001 Variance estimation of a survival function for interval-censored survival data Stat Med 20 8 1249 1257 10.1002/sim.719 11304740 10.1002/sim.719 1:STN:280:DC%2BD3MzpsFaqsg%3D%3D
24. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 2 229 235 10.1007/s10549-006-9242-8 16932852 10.1007/s10549-006-9242-8
25. MF Rimawi PB Shetty HL Weiss R Schiff CK Osborne GC Chamness RM Elledge 2010 Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes Cancer 116 5 1234 1242 10.1002/cncr.24816 20082448 10.1002/cncr.24816
26. G Somlo P Chu P Frankel W Ye S Groshen JH Doroshow K Danenberg P Danenberg 2008 Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome Ann Oncol 19 11 1853 1859 10.1093/annonc/mdn402 18641005 10.1093/annonc/mdn402 1:STN:280:DC%2BD1cnosVKgug%3D%3D
27. CL Arteaga A O'Neill SL Moulder M Pins JA Sparano GW Sledge NE Davidson 2008 A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer Clin Cancer Res 14 19 6277 6283 10.1158/1078-0432.CCR- 08-0482 18829509 10.1158/1078-0432.CCR-08-0482 1:CAS:528:DC%2BD1cXhtF2nurnO
28. Forbes JF, Pienkowski T, Valero V, Eiermann W, Von Minckwitz G, Martin M, Smylie M, Crown JM, Noel N, Pegram M, On behalf of the BCIRG007 investigators (2006) BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC). J Clin Oncol 24 (18S pt.II):LBA516
29. FJ Esteva H Guo S Zhang C Santa-Maria S Stone JS Lanchbury AA Sahin GN Hortobagyi D Yu 2010 PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer Am J Pathol 177 4 1647 1656 10.2353/ajpath.2010.090885 20813970 10.2353/ajpath.2010.090885 1:CAS:528:DC%2BC3cXhsVSqu7jO
30. D Cunningham Y Humblet S Siena D Khayat H Bleiberg A Santoro D Bets M Mueser A Harstrick C Verslype I Chau E Van Cutsem 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 337 345 10.1056/NEJMoa033025 15269313 10.1056/NEJMoa033025 1:CAS:528:DC%2BD2cXlvFGitbk%3D
31. LB Saltz NJ Meropol PJ Loehrer Sr MN Needle J Kopit RJ Mayer 2004 Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 7 1201 1208 10.1200/JCO.2004.10.182 14993230 10.1200/JCO.2004.10.182 1:CAS:528: DC%2BD2cXpsVGktLw%3D
32. KY Chung J Shia NE Kemeny M Shah GK Schwartz A Tse A Hamilton D Pan D Schrag L Schwartz DS Klimstra D Fridman DP Kelsen LB Saltz 2005 Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 9 1803 1810 10.1200/JCO.2005.08.037 15677699 10.1200/JCO.2005.08.037 1:CAS:528:DC%2BD2MXjt1Ckuro%3D
33. FR Hirsch M Varella-Garcia R Dziadziuszko Y Xiao S Gajapathy M Skokan M Lin V O'Neill PA Bunn Jr 2008 Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer Clin Cancer Res 14 19 6317 6323 10.1158/1078-0432.CCR-08-0539 18829515 10.1158/1078-0432.CCR-08-0539 1:CAS:528:DC%2BD1cXhtF2nurnE
34. TS Mok YL Wu S Thongprasert CH Yang DT Chu N Saijo P Sunpaweravong B Han B Margono Y Ichinose Y Nishiwaki Y Ohe JJ Yang B Chewaskulyong H Jiang EL Duffield CL Watkins AA Armour M Fukuoka 2009 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 10 947 957 10.1056/NEJMoa0810699 19692680 10.1056/NEJMoa0810699 1:CAS:528:DC%2BD1MXhtVygsbfK
35. F Pinter J Papay A Almasi Z Sapi E Szabo M Kanya A Tamasi B Jori E Varkondi J Moldvay K Szondy G Keri M Dominici P Conte S Eckhardt L Kopper R Schwab I Petak 2008 Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry J Mol Diagn 10 2 160 168 10.2353/jmoldx.2008.070125 18258923 10.2353/jmoldx.2008. 070125 1:CAS:528:DC%2BD1cXktFejt7c%3D